Illumina and the European Commission spent this afternoon fielding more than three hours of pointed questioning from the panel of judges considering the US biotech giant's appeal of the EU regulator's assertion of jurisdiction to review its buyout of cancer-test pioneer Grail.
This morning, Illumina told the EU's General Court that the two